[Research of prognostic immunophenotypes in 163 patients of diffuse large B-cell lymphoma].

To screen and analyze the prognostic protein biomarkers of DLBCL, and to explore their value in the prognostic evaluation. 163 cases of confirmed DLBCLs from January 2011 to December 2016 were collected with their clinical, pathological and follow-up data, which were all from our hospital. The expression of protein markers were tested using immunohistochemical staining (IHC) . The immune phenotypes independent of the International Prognostic Index (IPI) that affect overall survival (OS) and progression-free survival (PFS) of DLBCL were explored by COX regression model, and the effect of their co-expression on the prognosis were also analyzed. BCL6 negative (PFS: =1.652, 95% 1.030-2.649, =0.037) , P53 positive (OS: =1.842, 95% 1.008-3.367, =0.047) , and BCL2 strong positive expressions (S+) (OS: =2.102, 95% 1.249-3.537, =0.005; PFS: =2.126, 95% 1.312-3.443, =0.002) are adverse prognostic factors of DLBCL that are independent of IPI. BCL6(-) (PFS: =2.042, 95% 1.021-4.081, =0.043) , P53(+) (OS: =3.069, 95% 1.244-7.569, =0.015) and BCL2(S+) (OS: =2.433, 95% 1.165-5.082, =0.018; PFS: =3.209, 95% 1.606-6.410, =0.001) are adverse prognostic factors in the group of age≤60-year-old; in the group of IPI score 0-2, cases with BCL6(-) (OS: =2.467, 95% 1.322-4.604, =0.005; PFS: =2.248, 95% 1.275-3.965, =0.005) and BCL2(S+) (PFS: =2.045, 95% 1.119-3.735, =0.020) have worse prognosis. The co-expression of BCL6(-) and BCL2(S+) has significant influence on prognosis of DLBCL (=0.005 and <0.001) , in which BCL6(+)/non-BCL2(S+) (=86) has the best prognosis[3-year-OS (71.6±4.9) %, 3-year-PFS (67.0±5.1) %], and BCL6(-)/BCL2(S+) (=10) has the worst prognosis[3-year-OS (20.0±12.6) %, 3-year-PFS (10.0±9.5) %]; the co-expression of BCL6(-) and P53(+) has no significant influence on prognosis (=0.061 and =0.089) , however, those cases with BCL6(+)/P53(-) (=98) often get better prognosis[3-year-OS (70.6±4.7) %, 3-year-PFS (64.6±4.9) %] than others; the co-expression of P53(+) and BCL2(S+) has significant influence on prognosis of DLBCL (<0.001 and <0.001) , and P53(+)/BCL2(S+) (=5) has the worst prognosis (3-year-OS and 3-year-PFS are both 0) ; BCL2(S+) cases get shorter OS and PFS, regardless of the expression of BCL6 and P53. The expression and co-expression of BCL6 negative, P53 positive and BCL2(S+) have certain value in the prognostic evaluation of DLBCL, especially in the group of age≤60-year-old and IPI score 0-2.